PMID- 34660469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211022
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 9
DP  - 2021
TI  - Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With 
      Elevated IgE Levels and Recurrent Skin Infections.
PG  - 646997
LID - 10.3389/fped.2021.646997 [doi]
LID - 646997
AB  - The efficacy of dupilumab in pediatric patients with severe eczema presenting in 
      the setting of elevated immunoglobulin E (IgE) levels and recurrent bacterial 
      skin infections is not well-understood. Here we present the case of a child with 
      elevated IgE levels in whom dupilumab treatment led to remarkable control of his 
      eczema and recurrent skin infections. We also review the use of dupilumab in 
      other patients with molecularly proven cases of hyper IgE (HIGE) syndrome. Our 
      case supports the notion that dupilumab may have a seminal application in 
      treating severe eczema that occurs in the setting of elevated IgE levels and 
      recurrent bacterial skin infections.
CI  - Copyright (c) 2021 Joshi, Anvari, Gupta, Davis and Hajjar.
FAU - Joshi, Tejas P
AU  - Joshi TP
AD  - Baylor College of Medicine, Houston, TX, United States.
FAU - Anvari, Sara
AU  - Anvari S
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
FAU - Gupta, Meera R
AU  - Gupta MR
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
FAU - Davis, Carla M
AU  - Davis CM
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
AD  - Wiliam T Shearer Center for Human Immunobiology, Texas Children's Hospital, 
      Houston, TX, United States.
FAU - Hajjar, Joud
AU  - Hajjar J
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
AD  - Wiliam T Shearer Center for Human Immunobiology, Texas Children's Hospital, 
      Houston, TX, United States.
LA  - eng
PT  - Case Reports
DEP - 20210929
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC8511520
OTO - NOTNLM
OT  - dupilumab
OT  - hyper-IgE syndrome
OT  - pediatrics-children
OT  - primary immunodeficencies
OT  - severe eczema
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/19 06:00
MHDA- 2021/10/19 06:01
PMCR- 2021/09/29
CRDT- 2021/10/18 09:07
PHST- 2020/12/28 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/10/18 09:07 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/19 06:01 [medline]
PHST- 2021/09/29 00:00 [pmc-release]
AID - 10.3389/fped.2021.646997 [doi]
PST - epublish
SO  - Front Pediatr. 2021 Sep 29;9:646997. doi: 10.3389/fped.2021.646997. eCollection 
      2021.